Search research articles
Contact Us
Filters
Showing results (111-120 of 152) with videos related to
Page
of 16
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 23, 2015
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient
Matthias Scheffler, Sabine Merkelbach-Bruse, Marc Bos, et al.
Blood Advances
|
January 27, 2026
Rapid molecular response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial
Jan-Michel Heger, Julia Mattlener, Peter Herhaus, et al.
Hemasphere
|
November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group
Andreas Engert, Helen Goergen, Jana Markova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2009
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus
Lucia Nogová, Ronald Boellaard, Carsten Kobe, et al.
Leukemia & Lymphoma
|
July 18, 2022
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
Stephanie Sasse, Paul Jan Bröckelmann, Jesko Momotow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 12, 2022
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial
Paul J Bröckelmann, Ina Bühnen, Julia Meissner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2014
Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe, Georg Kuhnert, Deniz Kahraman, et al.
Haematologica
|
February 26, 2026
Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis
Hishan Tharmaseelan, Lisa M Sgonina, Ina Bühnen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2020
Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial
Conrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, et al.
Blood
|
May 31, 2023
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies
Dennis A Eichenauer, Ina Bühnen, Christian Baues, et al.
Page
of 16
Search research articles
Search
Showing results (111-120 of 152) with videos related to
Sort By:
Page
of 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 23, 2015
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient
Matthias Scheffler, Sabine Merkelbach-Bruse, Marc Bos, et al.
Blood Advances
|
January 27, 2026
Rapid molecular response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial
Jan-Michel Heger, Julia Mattlener, Peter Herhaus, et al.
Hemasphere
|
November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group
Andreas Engert, Helen Goergen, Jana Markova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2009
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus
Lucia Nogová, Ronald Boellaard, Carsten Kobe, et al.
Leukemia & Lymphoma
|
July 18, 2022
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
Stephanie Sasse, Paul Jan Bröckelmann, Jesko Momotow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 12, 2022
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial
Paul J Bröckelmann, Ina Bühnen, Julia Meissner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2014
Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe, Georg Kuhnert, Deniz Kahraman, et al.
Haematologica
|
February 26, 2026
Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis
Hishan Tharmaseelan, Lisa M Sgonina, Ina Bühnen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2020
Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial
Conrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, et al.
Blood
|
May 31, 2023
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies
Dennis A Eichenauer, Ina Bühnen, Christian Baues, et al.
Page
of 16